The New York Times reports that nitroglycerine, the go-to drug in emergency rooms when physicians suspect an MI, may face intermittent shortages, according to its sole supplier.

The FDA approved three St. Jude Medical pacemaker devices, including its quadripolar cardiac resynchronization therapy pacemaker.

Ladies and gentlemen, start your rrr, rrr, rrr-rivaroxaban? NASCAR, the auto racing aficionado organization, announced that Janssen Pharmaceuticals has become its official cardiovascular partner.

The use of a leadless, self-contained pacemaker was found to be safe and effective in a group of patients with an indication for single-chamber pacing who participated in a clinical trial. The study results were published online March 24 in Circulation.

Citing two cases involving recalled leads in implantable cardiac devices as examples, two California researchers called for more postmarketing surveillance, publicly available data registries and better labeling to help physicians assess devices’ risks and benefits.

Patients with extensive middle-cerebral-artery stroke may benefit somewhat from hemicraniectomy, based on research published March 20 in the New England Journal of Medicine. The study found the procedure improved survival, but left many patients with considerable disability. 

Interventional cardiologists who participated in a 90-minute course that emphasized radiation safety principals reduced patient radiation dose by 48 percent in diagnostic catheterizations.

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC(tm)) technology for clinical diagnostics and scientific discovery, yesterday presented new data at the American Heart Association Epidemiology and Prevention Council Conference highlighting research results using the Company's proprietary ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). The study utilized the Erenna System to measure previously undetected increases in cTnI to predict development of coronary heart disease (CHD) in the general population, independent of a variety of traditional risk factors.